钇90 替伊莫单抗（泽瓦林）治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤：5例报告
Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases.
作者信息
Wang Jing, Baidoun Firas, Tun Han W, Alhaj Moustafa Muhamad
机构信息
Department of Internal Medicine, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.
Division of Hematology and Medical Oncology, Mayo Clinic Florida, Jacksonville, FL, 32224, USA.
出版信息
Blood Lymphat Cancer. 2023 Oct 3;13:59-65. doi: 10.2147/BLCTT.S398809. eCollection 2023.
Radioimmunotherapy (RIT) with radio-labeled monoclonal antibodies to CD20 produces a high response rate in patients with low-grade B-cell lymphomas. The use of this modality in patients with chronic lymphocytic leukemia (CLL) has been sporadic in clinical trials and was hampered by the extensive marrow involvement seen commonly in patients with CLL, which would produce a high risk for marrow aplasia after treatment with RIT. Herein, we report our experience with RIT in 5 patients with CLL or SLL showing short-lived responses and significant myelosuppression. After 90Y-ibritumomab tiuxetan treatment, the median time to relapse was 65 days, and no cases of MDS or AML were observed during follow-up. All patients experienced grade ≥3 thrombocytopenia and neutropenia, with median durations of 39.5 days and 107 days, respectively.
用放射性标记的抗CD20单克隆抗体进行放射免疫治疗（RIT）在低度B细胞淋巴瘤患者中产生了较高的缓解率。在慢性淋巴细胞白血病（CLL）患者中，这种治疗方式在临床试验中的应用较为零散，并且受到CLL患者常见的广泛骨髓受累的阻碍，这会导致RIT治疗后发生骨髓再生障碍的高风险。在此，我们报告了我们对5例CLL或SLL患者进行RIT治疗的经验，这些患者显示出短暂的缓解和明显的骨髓抑制。在用90Y-伊布替尼单抗治疗后，中位复发时间为65天，随访期间未观察到骨髓增生异常综合征（MDS）或急性髓系白血病（AML）病例。所有患者均出现≥3级血小板减少和中性粒细胞减少，中位持续时间分别为39.5天和107天。
Zotero 插件